Seres Therapeutics Inc. (MCRB) and the Battle of Fundamentals vs. Technicals – News Heater
Home  »  Business   »  Seres Therapeutics Inc. (MCRB) and the Battle of F...

Seres Therapeutics Inc. (MCRB) and the Battle of Fundamentals vs. Technicals

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Seres Therapeutics Inc. (NASDAQ:MCRB) went down by -6.06% from its latest closing price compared to the recent 1-year high of $38.50. The company’s stock price has collected -11.83% of loss in the last five trading sessions. Press Release reported on 09/07/21 that Seres Therapeutics to Participate in Upcoming Virtual Investor Conferences

Is It Worth Investing in Seres Therapeutics Inc. (NASDAQ :MCRB) Right Now?

Plus, the 36-month beta value for MCRB is at 3.98. Opinions of the stock are interesting as 7 analysts out of 9 who provided ratings for Seres Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 1 rated it as “hold,” and 1 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $20.57. MCRB currently public float of 83.41M and currently shorts hold a 7.62% ratio of that float. Today, the average trading volume of MCRB was 1.78M shares.

MCRB’s Market Performance

MCRB stocks went down by -11.83% for the week, with a monthly drop of -13.38% and a quarterly performance of -71.49%, while its annual performance rate touched -76.90%. The volatility ratio for the week stands at 8.51% while the volatility levels for the past 30 days are set at 6.12% for Seres Therapeutics Inc.. The simple moving average for the period of the last 20 days is -7.46% for MCRB stocks with a simple moving average of -70.03% for the last 200 days.

Analysts’ Opinion of MCRB

Many brokerage firms have already submitted their reports for MCRB stocks, with Goldman repeating the rating for MCRB by listing it as a “Sell.” The predicted price for MCRB in the upcoming period, according to Goldman is $7 based on the research report published on July 23rd of the current year 2021.

Goldman, on the other hand, stated in their research note that they expect to see MCRB reach a price target of $24. The rating they have provided for MCRB stocks is “Neutral” according to the report published on May 18th, 2021.

Chardan Capital Markets gave a rating of “Buy” to MCRB, setting the target price at $30 in the report published on March 05th of the current year.

MCRB Trading at -44.67% from the 50-Day Moving Average

After a stumble in the market that brought MCRB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -84.70% of loss for the given period.

Volatility was left at 6.12%, however, over the last 30 days, the volatility rate increased by 8.51%, as shares sank -11.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -73.94% lower at present.

During the last 5 trading sessions, MCRB fell by -11.83%, which changed the moving average for the period of 200-days by -80.80% in comparison to the 20-day moving average, which settled at $6.33. In addition, Seres Therapeutics Inc. saw -75.96% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at MCRB starting from Henn Matthew R., who sale 91,812 shares at the price of $27.04 back on Dec 01. After this action, Henn Matthew R. now owns 0 shares of Seres Therapeutics Inc., valued at $2,482,309 using the latest closing price.

Stock Fundamentals for MCRB

Current profitability levels for the company are sitting at:

  • -265.33 for the present operating margin

The net margin for Seres Therapeutics Inc. stands at -268.33. The total capital return value is set at -83.15, while invested capital returns managed to touch -88.27. Equity return is now at value -87.10, with -41.50 for asset returns.

Based on Seres Therapeutics Inc. (MCRB), the company’s capital structure generated 23.33 points at debt to equity in total, while total debt to capital is 18.92. Total debt to assets is 11.89, with long-term debt to equity ratio resting at 20.14. Finally, the long-term debt to capital ratio is 16.33.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 52.45, with the company’s debt to enterprise value settled at 0.02. The receivables turnover for the company is 5.95 and the total asset turnover is 0.14. The liquidity ratio also appears to be rather interesting for investors as it stands at 5.79.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam